The content of this webpage has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Reliance on this promotion for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets involved.
Investors
Investment round now OPEN.
Occuity's bold mission is to improve the lives of millions by improving the screening and monitoring of some of humanity's most prevalent diseases. If you share our vision and are looking for an ethical investment opportunity which also offers the potential for significant value creation, then please continue reading to explore this unique investment opportunity.
An Introduction to Occuity
A window on your health.
At Occuity, we’re pioneering the future of preventative health through Oculomics – the science of detecting and monitoring systemic disease via the eye.
Our mission is bold: to improve the lives of hundreds of millions of people by making the screening and monitoring of chronic conditions like myopia, diabetes, and Alzheimer’s accessible, painless and non-contact.
We’re achieving this through a globally patented optical technology platform that uses light to scan the eye – collecting vital health data in seconds, with no blood, no needles, and no discomfort.
With 15 patents, growing revenues from our first commercial product, and a strategic pipeline of handheld diagnostic devices, Occuity is building a platform for early detection, early action, and better patient outcomes.
Why Invest in Occuity
Occuity is entering a transformational stage.
With its first product generating revenue, a second - targeting a multibillion-pound market - close to launch, and a pipeline of non-invasive diagnostic devices, the company is poised for rapid growth and long-term value creation.
To build on this momentum, Occuity is raising c.£2 million (EIS eligible) to scale operations and accelerate commercial rollout. Funds from this round will be used to bring the AX1 to market, scale manufacturing, expand distribution, and drive revenue.
With the PM1 already generating income, a strong pipeline, and a proven team, Occuity offers a rare chance to back a British healthtech company with global ambition and a scalable, rapid growth strategy.
This round presents a compelling opportunity for existing shareholders and new investors to participate ahead of the launch of the AX1 — which promises to deliver large revenues and an anticipated uplift in Occuity’s valuation.
Download
Investment Round Details
2025 Funding Round:
-
Target Raise: £2m
-
EIS Eligible: Yes
-
Or Pref Shares for Non-EIS Investors
-
-
Share Price: £30
-
(25% uplift on last pre-revenue round)
-
-
Pre Money Valuation: £35m
-
Previously Raised £9m in Investment & £4m+ in Grants
-
-
ROI: Projecting 10x by 2029
Use of Funds:
-
Commercial scale-up of the PM1
-
Global launch of AX1
-
Continuing R&D support alongside grants
-
Funding for Oculomics Products
-
Working capital, operational growth & contingency to maintain momentum and mitigate risk
Register to Receive
Steps to Investment
Investors
Equity Shares
Experienced Investors - High Net Worth Individuals (HNWI) / Sophisticated & Professional.
Occuity is open to discussing investment from a range of investors. If you are able to self-certify as an investment professional, HNWI or sophisticated investor and would like to know more, then please complete the form to request our Investment Memorandum.
There are currently three investment options available.
Direct:
-
EIS eligible equity shares
-
Non-EIS shares for International Investors
Please note the minimum direct investment we are able to accept is £10,020
Republic (Seedrs) Crowdfunding
If you are interested in investing less than £10,020, this can be done through our crowdfunding campain on Republic (Seedrs). Register Now for Early Access.
Form 1 - Self Certify as HNW/Sophisticated Investor
& Sign NDA
Thank you for your interest in Occuity. To enable us to send you further information such as the Investor Memorandum, please complete the form below to self-certify and sign an NDA, due to the confidential nature of our detailed memorandum.
About Occuity
What if we could spot chronic diseases like myopia, diabetes, and Alzheimer’s… before the damage they cause shows up as symptoms?
What if a simple scan of the eye could change the future of healthcare?
At Occuity, we’re turning that vision into reality.
We’re using the eye as a window on to the health of the body and are leaders in the burgeoning field of Oculomics: the science of detecting and monitoring systemic disease through the eye.
Our mission is bold: to improve the lives of hundreds of millions of people by making screening and monitoring for chronic diseases like myopia, diabetes, and Alzheimer’s accessible, painless and non-invasive.
We’re achieving this through a globally patented optical platform that uses a low-power beam of light to scan the eye — collecting data in seconds, with no blood, no needles, and no discomfort.
With 15 patents, and a strategic roadmap of handheld screening and monitoring devices, Occuity is building a platform for the future of preventative healthcare — with the potential to shift the paradigm from reactive treatment to early intervention.
We’re not just building medical devices.
We’re building the future of diagnostics.
Disclaimer - IMPORTANT NOTICE - WARNING RE FINANCIAL PROMOTIONS
This webpage is exempt from the general restriction in section 21 of the Financial Services and Markets Act 2000 on the communication of invitations or inducements to engage in investment activity on the grounds it is made exclusively to ‘investment professionals’ within the meaning of Article 19 of the Financial Services and Markets Act (Financial Promotion) Order 2005 (FinProm); persons believed on reasonable grounds to be ‘certified high net worth individuals’ within the meaning of Article 48 FinProm; persons who are ‘certified sophisticated investors’ within the meaning of Article 50 FinProm; and persons who are ‘self-certified sophisticated investors’ within the meaning of Article 50A FinProm.
If you are in any doubt about the investment to which this Webpage relates, you are strongly recommended to consult an appropriately authorised financial adviser qualified to give advice in relation to investment in unquoted shares issued by single companies. An investment in Occuity Ltd. will not necessarily be suitable for all recipients of this information. Applications to subscribe for Shares will only be accepted at Occuity's discretion from persons eligible to invest.
In viewing this webpage (the “Webpage”), the recipient agrees and undertakes to keep strictly confidential and not disclose to any other person, the transaction contemplated herein and all information contained in the Document or otherwise provided to the recipient. The recipient also agrees and undertakes, upon request, to return promptly all material received from Occuity Ltd (“Occuity”) (including the Webpage) without retaining any copies thereof. The Document is for the exclusive use of the recipient and shall not be copied, reproduced, distributed or passed to others without prior written consent of an Occuity Director. In furnishing the Document to the recipient, Occuity undertakes no obligation to provide the recipient with access to any additional information. All registered names and trademarks used in this Webpage are acknowledged as belonging to their respective owners.
This document does not constitute an offer or invitation to the public to subscribe for or purchase any securities in the proposed business (“the Company”). Statements of belief, projections, forecasts and expectations in connection with the Company represent the Company’s own assessment and interpretation of information available to it at the date of this document. No representations or warranties are given as to the accuracy or completeness of the information (including without limitation all projections) or opinions expressed in this Webpage and no liability is accepted for any such information or opinions. Further, the information may be subject to updating revision and/or amendment. The Webpage does not purport to be all-inclusive or to contain all the information that a prospective investor may desire.
New investors must determine for themselves what reliance they should place on the statements, views, projections and forecasts. It is reiterated that this document is exempt from the general restriction in section 21 of the Financial Services and Markets Act 2000 on the communication of invitations or inducements to engage in investment activity on the grounds it is made exclusively to ‘investment professionals’ within the meaning of Article 19 of the Financial Services and Markets Act (Financial Promotion) Order 2005 (FinProm).
It is emphasised that this Webpage has been accessed by you relying upon your representation that you constitute a person to whom the financial promotion restriction in section 21 above does not apply by reason of the fact that you are either a ‘certified high net worth individual’ within the meaning of Article 48 FinProm; a ‘certified sophisticated investor’ within the meaning of Article 50 FinProm or a ‘self-certified sophisticated investor’ within the meaning of Article 50A FinProm (together “a Relevant Person”). This Webpage must not be acted on or relied on by persons who are not Relevant Persons.
Occuity, together with the Directors, advisers, representatives, agents, and employees, make no representation of warranty, express or implied in relation to, and accept no responsibility or liability for the accuracy or completeness of the Webpage or any other written or oral information transmitted or made available to the recipient or any prospective investor. Any prospective investor shall rely solely on its judgement, review and business analysis in its evaluation and nothing contained herein is, or shall be, relied upon as a promise or forecast of the future.